Overview

Price chart · mood · technical indicators

JAZZ

Jazz Pharmaceuticals PLCstock Healthcare

Biotechnology

$230.93112.25%Current Market Mood:Strong Bullish

Market Mood

Price Range (1Y)

$105.00$243.32

Current: $230.93

Idea: EMA

1Y Return

+55.0%

Sharpe 3Y

0.81

Market Comparison

vs Healthcare Sector & Biotechnology Industry

JAZZ

+112.25%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio1924.42Forward 12.69

EPS (TTM)$0.123.2% YoY

Profit margin0.7%HEALTHCARE

Market cap$14.49BLarge cap

Wall Street coverage

$253.21median target· current $106.58 (+137.6%)19 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 12.69
PEG ratio: 0.97
P/B: 3.22
P/S (TTM): 3.26
EV/EBITDA: 25.38

Profitability & growth

ROE (TTM): 0.7%
Operating margin: 23.5%
Revenue growth YoY: 19.1%
Dividend yield: —
Beta: 0.27

Last earnings

May 5, 2026 · Estimate $4.66 · Reported $6.34

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Jazz Pharmaceuticals PLC

Company profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: WATERLOO EXCHANGE, DUBLIN, IRELAND
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$14.49B

Shares outstanding$62.7M

52W high$243.32

52W low$105.00

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer

Overview

JAZZ

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia

Is Ziihera’s HERIZON-GEA-01 Success Reframing the Oncology Investment Case for Jazz Pharmaceuticals (JAZZ)?

Jazz Pharmaceuticals (JAZZ) director sells 6,000 shares in pre-set Rule 10b5-1 trade

JAZZ: Zanidatamab's clinical success drives rapid expansion into new oncology markets and indications

Insider Sell: Neena Patil Sells Shares of Jazz Pharmaceuticals P

Jazz Pharmaceuticals (NASDAQ: JAZZ) Form 144: 6,000-share sale by insider

Director at Jazz Pharmaceuticals (JAZZ) exercises 3,415 stock options

Jazz Pharmaceuticals (JAZZ) legal chief sells 1,192 shares under 10b5-1 plan

Jazz Pharmaceuticals (JAZZ) EVP exercises options and sells 6,907 shares

Jazz Pharmaceuticals PLC (JAZZ): CBD-Based Epidiolex Drug Sales Up 15%

A Look At Jazz Pharmaceuticals (JAZZ) Valuation After A Strong Multi Period Share Price Run

A Look At Jazz Pharmaceuticals (JAZZ) Valuation After A Strong Multi Period Share Price Run

Anne O’Riordan to Leave Jazz Board, Will Not Stand for Re-election

Jazz Pharmaceuticals (JAZZ) director Anne O’Riordan will not seek re-election after 2026

[144] Jazz Pharmaceuticals plc SEC Filing

Jazz director sells shares after option exercise | JAZZ Insider Trading

Jazz Pharmaceuticals (JAZZ) director sells 2,000 Ordinary Shares in open-market trade

Jazz Pharmaceuticals stock ticks up on positive trial data

JAZZ Maintained by Barclays -- Price Target Raised to $253

Jazz Pharmaceuticals Stock: Here’s What Analysts Are Saying After the Q1 Beat and August Catalyst

About Jazz Pharmaceuticals PLC

Classification

Company profile

JAZZ

Market Comparison

JAZZ Market Analysis

Overview

JAZZ

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia

Is Ziihera’s HERIZON-GEA-01 Success Reframing the Oncology Investment Case for Jazz Pharmaceuticals (JAZZ)?

Jazz Pharmaceuticals (JAZZ) director sells 6,000 shares in pre-set Rule 10b5-1 trade

JAZZ: Zanidatamab's clinical success drives rapid expansion into new oncology markets and indications

Insider Sell: Neena Patil Sells Shares of Jazz Pharmaceuticals P

Jazz Pharmaceuticals (NASDAQ: JAZZ) Form 144: 6,000-share sale by insider

Director at Jazz Pharmaceuticals (JAZZ) exercises 3,415 stock options

Jazz Pharmaceuticals (JAZZ) legal chief sells 1,192 shares under 10b5-1 plan

Jazz Pharmaceuticals (JAZZ) EVP exercises options and sells 6,907 shares

Jazz Pharmaceuticals PLC (JAZZ): CBD-Based Epidiolex Drug Sales Up 15%

A Look At Jazz Pharmaceuticals (JAZZ) Valuation After A Strong Multi Period Share Price Run

A Look At Jazz Pharmaceuticals (JAZZ) Valuation After A Strong Multi Period Share Price Run

Anne O’Riordan to Leave Jazz Board, Will Not Stand for Re-election

Jazz Pharmaceuticals (JAZZ) director Anne O’Riordan will not seek re-election after 2026

[144] Jazz Pharmaceuticals plc SEC Filing

Jazz director sells shares after option exercise | JAZZ Insider Trading

Jazz Pharmaceuticals (JAZZ) director sells 2,000 Ordinary Shares in open-market trade

Jazz Pharmaceuticals stock ticks up on positive trial data

JAZZ Maintained by Barclays -- Price Target Raised to $253

Jazz Pharmaceuticals Stock: Here’s What Analysts Are Saying After the Q1 Beat and August Catalyst

About Jazz Pharmaceuticals PLC

Classification

Company profile

JAZZ

Market Comparison